You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/refractory marginal zone lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Guangzhou, Guangdong, China
  • +10 more
Oct 8, 2023

Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

Recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • Miami, Florida
    University of Miami
Jul 12, 2022

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Lymphoma Trial in Milan (clarithromycin, oral, high dose)

Completed
  • Lymphoma
  • clarithromycin, oral, high dose
  • Milan, Italy
    Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte
Aug 10, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

Terminated
Has Results
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Miami, Florida
    University of Miami
Aug 23, 2022

Revlimid® Capsules General Drug Use-results Surveillance

Recruiting
  • Lymphoma Nonhodgkin
    • Japan, Japan
      Local Institution
    Jun 22, 2022

    Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • +6 more
    • Beijing, China
      Beijing Cancer Hospital
    Feb 6, 2023

    Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

    Withdrawn
    • Follicular Lymphoma ( FL)
    • Marginal Zone Lymphoma (MZL)
    • (no location specified)
    Jul 14, 2022

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

    Completed
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +8 more
    • PI3K inhibitor BKM120
    • +3 more
    • Atlanta, Georgia
    • +1 more
    Jun 27, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +23 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 23, 2022

    Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

    Recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +17 more
    • Nivolumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 16, 2022

    Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

    Active, not recruiting
    • Grade 1 Follicular Lymphoma
    • +6 more
    • Palo Alto, California
      Stanford University, School of Medicine
    Jun 13, 2022

    Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

    Completed
    Has Results
    • Marginal Zone Lymphoma
    • +2 more
    • Harbin, Heilongjiang, China
    • +3 more
    Oct 26, 2021